-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At present, the normalization of the national centralized drug procurement is steadily advancing, the quality consistency evaluation of generic drugs has been continuously accelerated, and the review of new drugs in China has further developed from quantity to quality to standardization
In recent years, with the increasing incidence of lung cancer worldwide, new lung cancer targeted drug products have continued to come out, which has developed from the first generation to the third generation
.
As of the first half of 2021, the Center for Drug Evaluation (CDE) of the State Food and Drug Administration has approved 17 non-small cell lung cancer targeted small molecule drugs, including 7 domestically developed Class I new drugs, and approved import registration of non-small cell lung cancer targets There are 10 small-molecule drugs, and 13 domestic non-small-cell lung cancer targeted small-molecule drugs have been approved
.
(Click the picture to enlarge )According to MENET data analysis, in 2020, the amount of targeted small molecule drugs for non-small cell lung cancer in public hospitals in key provinces and cities in China will reach 4.
5 billion yuan, an increase of 36.
91% over the previous year .
Among the 12 non-small cell lung cancer targeted small molecule drugs that have entered the information system of public hospitals in 22 key provinces and cities, AstraZeneca’s third-generation tyrosine kinase mutation targeted drug osimertinib tablets accounted for three points One .
According to data from AstraZeneca’s financial report, global sales of osimertinib reached US$4.
328 billion in 2020, an increase of 35.
72% over the previous year
.
Osimertinib is the first choice for the treatment of patients with T790M-positive non-small cell lung cancer.
On September 30, 2018, it was included in the medical insurance reimbursement list by the National Medical Security Administration, with a decrease of 71%, from the previous 52,800 yuan/box/month Up to the current 15,300 yuan/box/month
.
According to MENET data, the amount of domestic protein kinase inhibitor small molecule targeted drugs used in public hospitals in key provinces and cities in China in 2020 is about 2.
(Click on the picture to enlarge )
Zhengda Tianqing Pharmaceuticals ranks first with 6 major varieties including Anlotinib, Sunitinib, Afatinib, Dasatinib, Gefitinib, and Imatinib, occupying 43.
Targeted drugs for non-small cell lung cancer are thriving
In recent years, with the increasing incidence of lung cancer worldwide, new lung cancer targeted drug products have continued to come out, which has developed from the first generation to the third generation
.
As of the first half of 2021, the Center for Drug Evaluation (CDE) of the State Food and Drug Administration has approved 17 non-small cell lung cancer targeted small molecule drugs, including 7 domestically developed Class I new drugs, and approved import registration of non-small cell lung cancer targets There are 10 small-molecule drugs, and 13 domestic non-small-cell lung cancer targeted small-molecule drugs have been approved
.
(Click the picture to enlarge )According to MENET data analysis, in 2020, the amount of targeted small molecule drugs for non-small cell lung cancer in public hospitals in key provinces and cities in China will reach 4.
5 billion yuan, an increase of 36.
91% over the previous year .
Among the 12 non-small cell lung cancer targeted small molecule drugs that have entered the information system of public hospitals in 22 key provinces and cities, AstraZeneca’s third-generation tyrosine kinase mutation targeted drug osimertinib tablets accounted for three points One .
According to data from AstraZeneca’s financial report, global sales of osimertinib reached US$4.
328 billion in 2020, an increase of 35.
72% over the previous year
.
Osimertinib is the first choice for the treatment of patients with T790M-positive non-small cell lung cancer.
On September 30, 2018, it was included in the medical insurance reimbursement list by the National Medical Security Administration, with a decrease of 71%, from the previous 52,800 yuan/box/month Up to the current 15,300 yuan/box/month
.
